Octreotide is a medication used to treat certain types of tumors in the digestive system, known as gastroenteropancreatic neuroendocrine tumors. It works by mimicking a natural hormone in the body that helps to control the growth of these tumors. In this trial, octreotide is used in two forms: a long-acting release (LAR) version, which is designed to be released slowly over time, and a subcutaneous depot version called CAM2029, which is injected under the skin and also releases the medication slowly.

Lanreotide is another medication used to treat gastroenteropancreatic neuroendocrine tumors. Like octreotide, it mimics a natural hormone in the body to help control tumor growth. In this trial, lanreotide is used in a form called autogel (ATG), which is a long-acting injection that releases the medication slowly over time to help manage the condition.

Gastroenteropancreatic Neuroendocrine Tumors – These are a group of rare tumors that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. They are characterized by their ability to produce hormones, which can lead to various symptoms depending on the hormones released. The progression of these tumors can vary, with some growing slowly over many years, while others may grow more rapidly. They are often well-differentiated, meaning the tumor cells look similar to normal cells under a microscope. As the disease advances, it can spread to other parts of the body, such as the liver or lymph nodes. The course of the disease can be unpredictable, with periods of stability followed by progression.